



PYRIMIDINETHIONES AS BUILDING BLOCKS IN HETEROCYCLIC SYNTHESIS: SYNTHESIS OF PYRANO[2,3-D]PYRIMIDINE, CHROMENO[2,3-D]PYRIMIDINE, PYRIDO[3',2':5,6]PYRANO[2,3-B]PYRIDINE AND PYRIMIDO[5',4':5,6]PYRANO[2,3-D]PYRIMIDINE

Mohamed A. Elian, Ibrahim S. A. Hafiz, Mohamed A. M. Abdel Reheim

Dept. of Chemistry, Faculty of Education, Suez Canal University, El-Arish, Egypt.

ABSTRACT

A series of new thioxopyrimidine, 4H-pyrans, pyranopyridine and pyranopyrimidine derivatives with expected biological activity have been prepared through the reaction of 6-phenyl-2-thioxo-2,3-dihydropyrimidin-4(5H)-one **4** and 7-Amino-5-(4-chlorophenyl)-4-phenyl-2-thioxo-2,5-dihydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile **11b** with some electrophilic reagents and nucleophilic reagents. The newly synthesized compounds were characterized by IR, ¹H-NMR and mass spectral studies.

Key Words: Thioxopyrimidine, 4H-pyrans, pyranopyridine and pyranopyrimidine

INTRODUCTION

Thioxopyrimidine is an essential structural unit of several heterocycles, which display a wide range of interesting biological and pharmacological properties such as anticancer and antimicrobial activities (Cocco *et al*, 2001).

Also, pyrimidinethiones have been found to possess antitubercular (Paghdar *et al*, 2007), antitumor (Ozaki *et al*, 1984) and hypoglycemic activities (Baucer and Safir, 1968).

On the other hand, 4H-pyrans and their derivatives are of considerable interest due to their pharmacological activities (Green *et al*, 1995), such as spasmolytic, diuretic, anticoagulant, anticancer, and antianaphylactic activity (abdelrazek *et al*, 2007; Bonsignore *et al*, 1993; Witte *et al*, 1986). In addition, 4H-pyrans are useful intermediates for synthesis of various compounds, such as pyranopyridine derivatives (Lei and Hu, 2011) and pyranopyrimidines (Quintela *et al*, 1995).

Also, various pyranopyrimidines exhibit antimicrobial (Eid *et al*, 2004), antibacterial (Abd El-Wahab, 2002), antigenotoxic (Chabchoub *et al*, 2007) and antifungal activities (Bedar *et al*, 2000; Bedar *et al*, 2000; Khafagy *et al*, 2002).

Moreover, pyranopyrimidines derivatives can have antiplatelet, antithrombotic (Bruno *et al*, 2006), analgesic, anti-inflammatory, and antiphlogistic activity (Bruno *et al*, 2004; Bruno *et al*, 2002).

In view of these observations and in continuation of our previous work in heterocyclic chemistry, we synthesized some new pyranopyrimidinethione and chromenopyrimidinethione derivatives using 6-phenyl-2-thioxo-2,3-dihydropyrimidin-4(5H)-one as starting materials aiming to develop a new synthetic route for synthesing new heterocyclic derivatives.

RESULTS AND DISCUSSIONS

Pyrimidinethione **4** was prepared through the two-component reaction of thiourea and ethylbenzoylacetate. The structure of the reaction product could be

established via inspection of its IR, ^1H -NMR and mass spectra [Mahmoud *et al.*, 2012]. The isomeric structure **5** can be isolated in lower yield (5%) (Scheme 1). The active methylene group in 2-thioxo-2,3-dihydropyrimidine derivatives **4** was exploited to synthesize novel pyranopyrimidine, chromenopyrimidinethione and pyrido [3',2':5,6]pyrano [2,3-b] pyridine derivatives through its reactions with some electrophile reagents.


Thus, Compounds **11a-e** were synthesized in quantitative yield, when **4** is allowed to react with arylidenemalononitrile derivatives **6a-e** under reflux in ethanol and in the presence of catalytic amounts of piperidine.

The structure of compound **11a** was established based on analytical and spectral data [Mahmoud *et al.*, 2012; Saied *et al.*; Hala and Mona, 2012]. In a similar manner, the reaction of **4** with α , β -unsaturated ketones **12a-c** in the presence of piperidine led to the formation of pyranopyrimidinethione derivatives **16a-c** [El-saied *et al.*, 2004] (Scheme 2). A mixture of formaldehyde and malononitrile was reacted with compound **4** in refluxing ethanol/piperidine to give **20** [Elagamy *et al.*, 2006; El-Gaby *et al.*, 2006]. Pyranopyrimidine carbonitrile derivatives **24a-b** was synthesized by cyclocondensation of compound **4** with ethoxymethylenemalononitrile, ethyl-2-cyano-3-ethoxyacrylate **21a,b** in refluxing ethanol and catalytic amounts of piperidine.


The structure of **24a** was established on the basis of its elemental analysis and spectral data. Compound **24b** is assumed to be formed via intermediate formation followed by elimination of ethanol.

In a similar manner, cyclization of benzylidene cyclohexanone derivatives **25a-d** with dihydropyrimidinone derivatives **4** in ethanol at reflux temperature in the presence of piperidine produced the chromenopyrimidinethione derivatives **29a-d** [El-Gaby *et al.*, 2006], all the analytical and spectral data of compounds **29a-d** are in agreement with the proposed structures.

The formation of **29a-d** were proposed to proceed via the Michael type addition of the active methylene group in dihydropyrimidinone derivatives **4** to the activated double bond in **25a-d** to give Michael adducts which readily cyclized to yield **29a-d** via losing water molecule (Scheme 3). In continuation of our previous interest in the synthesis of variety of heterocycles from readily obtainable inexpensive starting materials we report here on the utility of 7-amino-5-(4-chlorophenyl-4-phenyl-2-thioxo-2,5-dihydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile **11b** for the synthesis of some novel heterocycles in incorporating pyrimidinethione moiety. So, when compound **11b** allowed to react with chloroacetylchloride **30** in refluxing dioxane it afforded the novel 2-chloroacetimidate derivatives **31** in acceptable yield (80%).



Scheme 1



The structure of compound 31 was established on the basis of analytical and spectral data. Furthermore the reaction of 11b with chloroacetylchloride 30 in dioxane under reflux for 24 hrs gave pyrano[2,3-d:6,5-d']dipyrimidin-6(2H)-one derivatives 32. Compound 32 was obtained by fusion of compound 31 over melting point without solvent in presence of ammonium acetate [Mansour et al, 2011; Afaf et al 2013].

Compound 11b was reacted with benzylidenemalononitrile 6a in ethanol in the presence of a catalytic amount of piperidine under reflux to give the corresponding pyrido [3',2':5,6] pyrano [2,3-d] pyrimidine-7-carbonitrile 33.

The IR, ¹H-NMR and mass spectra of compound 33 is in agreement with the proposed structure (El-Gaby et al., 2006) (scheme 4) Compound 11b condensed with dimethylformamidedimethylacetal (DMF-DMA) to yield 34. The Pyrimidinethiones derivatives 35 was obtained by the reaction of compound 11b with formamide. Compound 34 could be readily converted in to pyrano[2,3-d]pyrimidine 35 on treatment with AcOH in the presence of ammonium acetate mixture. Structure of compound 35 was established through spectral analysis (Said et al., 2007; Gamal et al., 2005; Nada et al.; 2008) (Scheme 4).




EXPERIMENTS

Melting points were determined using a Büchi apparatus and are uncorrected. The purity of compound was confirmed by TLC using Merck silica gel 60F₂₅₄ plates using toluene, ethyl acetate and methanol as a mobile phase and spots were visualized under UV radiation. IR spectra (KBr) were recorded on a Bruker-Vector 22 instrument (Bruker) and frequencies are expressed in cm⁻¹. ¹H NMR spectra were recorded with a Varian Gemini spectrometer (300 MHz and 200 MHz) with TMS as the internal reference. Chemical shifts were reported on ppm scale (δ) relative to TMS as a standard.

The mass spectra were recorded with a HP D5988 A 1000 MHz instrument (Hewlett-Packard). Elemental analyses were performed at the Microanalytical Centre at the Faculty of Science, Cairo University, Egypt.

procedure for the preparation of compounds (4,5).

A mixture of thiourea (0.76 g, 0.01 mol) and ethyl benzoylacetate (1.92 g, 0.01 mol) was stirred overnight without solvent for 24 hrs at room temperature. The solid product formed was filtered off, washed with diethyl ether and crystallized from ethanol to give (4, 5).



6-phenyl-2-thioxo-2,3-dihydropyrimidin-4(5H)-one (4). It was obtained as white crystals yield (83%); m.p.145—147°C; $^1\text{H-NMR}$ (DMSO— d_6) δ : 4.17 (s, 2H, CH₂), 7.02—7.57 (m, 6H, aromatic H and NH); IR (KBr) ν cm⁻¹: 3380 (NH), 3175 (CH—arom), 1618 (C=O) cm⁻¹; MS: m/z (%) 205 (M⁺+1), Anal. calcd for C₁₀H₈N₂OS (204): C, 58.80; H, 3.95; N, 13.72; S, 15.70; Found: C, 58.82; H, 3.97; N, 13.73; S, 15.69 %.

7-hydroxy-4-phenylpyrimidine-2(1H)-thione (5).

It was obtained as yellow crystals yield (5%); m.p.240—242 °C; $^1\text{H-NMR}$ (DMSO— d_6) δ : 6.07 (s, 1H, CH—oliffin), 7.48—7.70 (m, 6H, aromatic H and NH), 12.49 (s, 1H, OH); IR (KBr) ν cm⁻¹ : 3400 (OH), 3159 (NH) cm⁻¹; MS: m/z (%) 205 (M⁺+1), Anal. calcd for C₁₀H₈N₂OS (204): C, 58.80; H, 3.95; N, 13.72; S, 15.70; Found: C, 58.81; H, 3.96; N, 13.74; S, 15.69 %.

procedure for the preparation of pyranopyrimidine derivatives (11a—e).

A mixture of dihydropyrimidinone derivatives (4) (2.04 g; 0.01 mol) and arylidenemalononitriles (6a—e) (0.01 mol) in ethanol (50 mL) containing catalytic amount of piperidine was heated under reflux for 12 hrs. The reaction mixture was allowed to cool and poured into crushed ice then acidified with HCl. The separated solid was filtered off, washed with water and crystallized to give (11a—e).

7-Amino-4,5-diphenyl-2-thioxo-2,5-dihydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile (11a).

Formed as white crystals from ethanol; yield (82%); m.p.108—110 °C; $^1\text{H-NMR}$ (DMSO— d_6) δ : 4.97 (s, 1H, 4H—pyrane), 6.13 (s, 2H, NH₂); 9.73 (s, 1H, NH), 7.05—7.79 (m, 10H, aromatic H); IR (KBr) ν cm⁻¹: 3329, 3203 (NH₂), 3050 (CH—arom), 2934 (CH—aliph), 2185

(CN) cm⁻¹; MS: m/z (%) 359 (M⁺+1), Anal. calcd for C₂₀H₁₄N₄OS (358): C, 67.02; H, 3.94; N, 15.63; S, 8.95; Found: C, 67.02; H, 3.95; N, 15.65; S, 8.93 %.

7-Amino-5-(4-chlorophenyl)-4-phenyl-2-thioxo-2,5-dihydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile (11b).

Formed as yellow crystals from ethanol; yield (84%); m.p.186—188 °C; $^1\text{H-NMR}$ (DMSO— d_6) δ : 5.02 (s, 1H, 4H—pyrane), 6.15 (s, 2H, NH₂), 7.00—7.84 (m, 10H, aromatic H and NH); IR (KBr) ν cm⁻¹: 3471, 3332 (NH₂), 3226 (NH), 2924 (CH—aliph), 2218 (CN) cm⁻¹; MS: m/z (%) 392 (M⁺), Anal. calcd for C₂₀H₁₃ClN₄OS (392): C, 61.14; H, 3.34; N, 14.26; Cl, 9.02; S, 8.16; Found: C, 61.15; H, 3.36; N, 14.27; Cl, 9.01; S, 8.15 %.

7-Amino-5-(2-nitrophenyl)-4-phenyl-2-thioxo-2,5-dihydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile (11c).

Formed as pale yellow crystals from ethanol; yield (78%); m.p.150-152 °C; $^1\text{H-NMR}$ (CDCl₃) δ : 4.38 (s, 1H, 4H—pyrane), 6.62 (s, 2H, NH₂), 6.95—8.54 (m, 9H, aromatic H), 9.28 (s, 1H, NH); IR (KBr) ν cm⁻¹: 3336, 3200 (NH₂), 2936 (CH—aliph), 2191 (CN) cm⁻¹; MS: m/z (%) 403 (M⁺), Anal. calcd for C₂₀H₁₃N₅O₃S (403): C, 59.55; H, 3.25; N, 17.36; S, 7.95; Found: C, 59.56; H, 3.27; N, 17.37; S, 7.94 %.

7-Amino-5-(4-methoxyphenyl)-4-phenyl-2-thioxo-2,5-dihydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile (11d).

Formed as green crystals from ethanol; yield (70%); m.p.180-182 °C; $^1\text{H-NMR}$ (DMSO— d_6) δ : 3.71 (s, 3H, OCH₃), 3.84 (s, 1H, 4H—pyrane), 7.02—7.85 (m, 12H, aromatic H+NH₂); IR (KBr) ν cm⁻¹: 3401, 3214 (NH₂), 2933 (CH—aliph), 2197 (CN) cm⁻¹; MS: m/z (%) 388 (M⁺), Anal. calcd for C₂₁H₁₆N₄O₂S (388): C, 64.93; H, 4.15; N, 14.42; S, 8.25; Found: C, 64.94; H, 4.16; N, 14.44; S, 8.23 %.

7-Amino-5-methyl-4-phenyl-2-thioxo-2,5-dihydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile (11e).

Formed as pale green crystals from ethanol; yield (78%); m.p. 170—172 °C; $^1\text{H-NMR}$ (DMSO- d_6) δ : 2.27 (s, 3H, CH₃), 4.09 (s, 1H, 4H—pyrane), 6.22 (s, 2H, NH₂), 6.39—8.04 (m, 6H, aromatic H and NH); IR (KBr) ν cm⁻¹: 3349, 3228 (NH₂), 2932 (CH—aliph), 2193 (CN) cm⁻¹; MS: m/z (%) 296 (M⁺), Anal. calcd for C₁₅H₁₂N₄OS (296): C, 60.79; H, 4.08; N, 18.91; S, 10.82; Found: C, 60.80; H, 4.09; N, 18.93; S, 10.81 %.

procedure for the preparation of pyranopyrimidinethione derivatives (16a—c).

A mixture of dihydropyrimidinone derivatives (**4**) (2.04 g; 0.01 mol) and chalcones (**12a—c**) (0.01 mol) in ethanol (30 mL) containing catalytic amount of piperidine was heated under reflux for 24 hrs. The reaction mixture was allowed to cool and poured into crushed ice then acidified with HCl. The separated solid was filtered off, washed with water and crystallized from the proper solvent to give (**16a—c**).

4,5,7-triphenyl-1H-pyrano[2,3-d]pyrimidine-2(5H)-thione (16a).

Formed as pale yellow crystals from ethanol; yield (88%); m.p. 100—102 °C; $^1\text{H-NMR}$ (DMSO- d_6) δ : 5.10—5.11 (d, 1H, CH—oliffin), 5.38—5.40 (d, 1H, 4H—pyrane), 6.78—8.53 (m, 15H, aromatic H), 9.88 (s, 1H, NH); IR (KBr) ν cm⁻¹: 3181 (NH), 3083 (CH—arom), 2962 (CH—aliph) cm⁻¹; MS: m/z (%) 394 (M⁺), Anal. calcd for C₂₅H₁₈N₂OS (394): C, 76.12; H, 4.60; N, 7.10; S, 8.13; Found: C, 76.13; H, 4.62; N, 7.11; S, 8.11 %.

5-(4-chlorophenyl)-4,7-diphenyl-1H-pyrano[2,3-d]pyrimidine-2(5H)-thione (16b). Formed as pale yellow crystals from ethanol; yield (82%); m.p. 104—106

°C; $^1\text{H-NMR}$ (DMSO- d_6) δ : 5.12—5.15 (d, 1H, CH—oliffin), 5.37—5.66 (d, 1H, 4H—pyrane), 7.03—9.90 (m, 14H, aromatic H), 10.00 (s, 1H, NH); IR (KBr) ν cm⁻¹: 3194 (NH), 3050 (CH—arom), 2950 (CH—aliph) cm⁻¹; MS: m/z (%) 428 (M⁺), Anal. calcd for C₂₅H₁₇ClN₂OS (428): C, 70.00; H, 3.99; N, 6.53; Cl, 8.27; S, 7.48; Found: C, 69.99; H, 3.97; N, 6.52; Cl, 8.26; S, 7.47 %.

5-(4-methoxyphenyl)-4,7-diphenyl-1H-pyrano[2,3-d]pyrimidine-2(5H)-thione (16c).

Formed as pale yellow crystals from ethanol; yield (72%); m.p. 98—100 °C; $^1\text{H-NMR}$ (DMSO- d_6) δ : 3.84 (s, 3H, OCH₃), 3.91—3.94 (d, 1H, CH—oliffin), 5.32—5.34 (d, 1H, 4H—pyrane), 6.97—8.10 (m, 14H, aromatic H), 9.65 (s, 1H, NH); IR (KBr) ν cm⁻¹: 3272 (NH), 3050 (CH—arom) cm⁻¹; MS: m/z (%) 425 (M⁺+1), Anal. calcd for C₂₆H₂₀N₂O₂S (424): C, 73.56; H, 4.75; N, 6.60; S, 7.55; Found: C, 73.57; H, 4.76; N, 6.61; S, 7.53 %.

procedure for the preparation of pyranopyrimidine derivatives (20).

A mixture of dihydropyrimidinone derivatives (**4**) (2.04 g; 0.01 mol) and formaldehyde/malononitrile (0.01 mol) in ethanol (50 mL) containing catalytic amount of piperidine was heated under reflux for 24 hrs, then left to cool and poured into crushed ice then acidified with HCl. The solid product was filtered off, washed with water and crystallized from the proper solvent to give (**20**).

7-Amino-4-phenyl-2-thioxo-2,5-dihydro-1H-pyrano[2,3-d]pyrimidine-6-carbonitrile(20).

Formed as brown crystals from ethanol; yield (73%); m.p. 258—260 °C; $^1\text{H-NMR}$ (DMSO- d_6) δ : 4.12 (s, 2H, CH₂), 6.72 (s, 2H, NH₂), 6.99—8.86 (m, 5H, aromatic H), 12.00 (hump, 1H, NH); IR (KBr) ν cm⁻¹: 3330, 3179 (NH₂), 2926

(CH—aliph), 2203 (CN) cm^{-1} ; MS: m/z (%) 283 ($M^+ + 1$), Anal. calcd for $\text{C}_{14}\text{H}_{10}\text{N}_4\text{OS}$ (282): C, 59.56; H, 3.57; N, 19.85; S, 11.36; Found: C, 59.55; H, 3.55; N, 19.84; S, 11.34 %.

procedure for the preparation of pyranopyrimidine carbonitrile derivatives (24a,b) .

A mixture of dihydropyrimidinone derivatives (**4**) (2.04 g; 0.01 mol) and 2-ethoxymethylene malononitrile (**21a**), ethyl-2-cyano-3-ethoxyacrylate (**21b**) (0.01 mol) in ethanol (50 mL) containing catalytic amount of piperidine was heated under reflux for 24 hrs.

The reaction mixture was allowed to cool and poured into crushed ice then acidified with HCl. The separated solid was filtered, washed with excess of water and crystallized from the proper solvent to give the pyranopyrimidine carbonitrile derivative (**24a,b**).

7-Imino-4-phenyl-2-thioxo-2,7-1H-pyrano[2,3-*d*]pyrimidine-6-carbonitrile (24a). Formed as brown crystals from ethanol; yield (78%); m.p.288—290 °C; ^1H —NMR ($\text{DMSO}-d_6$) δ : 1.63 (s, H, NH); 1.90 (s, 1H, NH), 6.40—7.01 (m, 6H, aromatic H and CH—oliffinic); IR (KBr) ν cm^{-1} : 3420, 3339 (2NH), 2924 (CH—aliph), 2210 (CN) cm^{-1} ; MS: m/z (%) 280 (M^+), Anal. Calcd for $\text{C}_{14}\text{H}_8\text{N}_4\text{OS}$ (280): C, 59.99; H, 2.88; N, 19.99; S, 11.44; Found: C, 60.00; H, 2.89; N, 20.01; S, 11.42 %.

7-Oxo-4-phenyl-2-thioxo-2,7-1H-pyrano[2,3-*d*]pyrimidine-6-carbonitrile (24b). Formed as yellow crystals from ethanol; yield (83%); m.p.108—110 °C; ^1H —NMR ($\text{DMSO}-d_6$) δ : 1.56 (s, 1H, NH), 5.09 (s, 1H, CH—oliffin), 7.01—7.77 (m, 5H, aromatic H); IR (KBr) ν cm^{-1} : 3382 (NH), 2955 (CH—aliph), 2201 (CN), 1616 (C=O) cm^{-1} ; MS: m/z (%) 281 (M^+), Anal.

Calcd for $\text{C}_{14}\text{H}_7\text{N}_3\text{O}_2\text{S}$ (281): C, 59.78; H, 2.51; N, 14.94; S, 11.40; Found: C, 59.79; H, 2.53; N, 14.95; S, 11.39 %.

procedure for the preparation of chromenopyrimidinethione derivatives (29a-d).

A mixture of dihydropyrimidinone derivatives (**4**) (2.04 g; 0.01 mol) and benzylidenecyclohexanone derivatives (**25a-d**) (0.01 mol) in ethanol (30 mL) containing catalytic amount of piperidine was heated under reflux for 24 hrs.

The reaction mixture was allowed to cool and poured into crushed ice then acidified with HCl. The separated solid was filtered, washed with water and crystallized from the proper solvent to give (**29a-d**).

4,5-diphenyl-6,7,8,9-tetrahydro-1H-chromeno[2,3-*d*]pyrimidine-2(5H)-thione (29a).

Formed as pale yellow crystals from ethanol; yield (84%); m.p.105—107 °C; ^1H —NMR (CDCl_3) δ : 1.22—1.40 (m, 4H, 2CH₂), 1.43—3.33 (m, 4H, 2CH₂), 3.71 (s, 1H, 4H—pyrane), 6.95—7.56 (m, 10H, aromatic H), 7.81 (s, 1H, NH); IR (KBr) ν cm^{-1} : 3420 (NH), 3056 (CH—arom), 2932 (CH—aliph) cm^{-1} ; MS: m/z (%) 372 (M^+), Anal. Calcd for $\text{C}_{23}\text{H}_{20}\text{N}_2\text{OS}$ (372): C, 74.16; H, 5.41; N, 7.52; S, 8.61; Found: C, 74.17; H, 5.42; N, 7.50; S, 8.60 %.

5-(4-chlorophenyl)-4-phenyl-6,7,8,9-tetrahydro-1H-chromeno[2,3-*d*]pyrimidine-2(5H)-thione (29b).

Formed as pale yellow crystals from ethanol; yield (86%); m.p.111—113 °C; ^1H —NMR (CDCl_3) δ : 0.75—1.97 (m, 4H, 2CH₂), 2.09—3.93 (m, 4H, 2CH₂), 4.37 (s, 1H, 4H—pyrane), 6.67—8.01 (m, 9H, aromatic H); 9.35 (s, 1H, NH); IR (KBr) ν cm^{-1} : 3418 (NH), 3058 (CH—arom), 2932 (CH—aliph) cm^{-1} ; MS: m/z (%) 407 ($M^+ + 1$), Anal. calcd for $\text{C}_{23}\text{H}_{19}\text{ClN}_2\text{OS}$ (406): C, 67.89; H, 4.71;

N, 6.88; Cl, 8.71; S, 7.88; Found: C, 67.90; H, 4.72; N, 6.90; Cl, 8.70; S, 7.87 %.

5-(4-methoxyphenyl)-4-phenyl-6,7,8,9-tetrahydro-1H-chromeno[2,3-d]pyrimidine-2(5H)-thione (29c).

Formed as yellow crystals from ethanol; yield (81%); m.p.140—142 °C; ¹H—NMR (CDCl₃) δ: 1.79—2.18 (m, 4H, 2CH₂), 2.90—2.94 (m, 4H, 2CH₂), 3.85 (s, 3H, OCH₃), 3.89 (s, 1H, 4H—pyrane), 6.92—7.78 (m, 10H, aromatic H and NH); IR (KBr) cm⁻¹: 3381 (NH), 2938 (CH—aliph) cm⁻¹; MS: *m/z* (%) 402 (M⁺), Anal. Calcd for C₂₄H₂₂N₂O₂S (402): C, 71.62; H, 5.51; N, 6.96; S, 7.97; Found: C, 71.61; H, 5.50; N, 6.94; S, 7.95 %.

5-(4-hydroxyphenyl)-4-phenyl-6,7,8,9-tetrahydro-1H-chromeno[2,3-d]pyrimidine-2(5H)-thione (29d).

Formed as pale yellow crystals from ethanol; yield (80%); m.p.102—104 °C; ¹H—NMR (DMSO—*d*₆) δ: 0.88—1.56 (m, 4H, 2CH₂), 1.90—2.40 (m, 4H, 2CH₂), 3.73 (s, 1H, 4H—pyrane), 6.65—7.42 (m, 9H, aromatic H), 8.25 (s, 1H, NH), 9.12 (s, 1H, OH); IR (KBr) v cm⁻¹: 3339 (NH), 3060 (CH—arom), 2932 (CH—aliph) cm⁻¹; MS: *m/z* (%) 388 (M⁺), Anal. calcd for C₂₃H₂₀N₂O₂S (388): C, 71.11; H, 5.19; N, 7.21; S, 8.25; Found: C, 71.10; H, 5.18; N, 7.20; S, 8.24 %.

procedure for the preparation of compound (31).

A mixture of (11b) (3.92 g; 0.01 mol) and 2-chloroacetyl chloride (30) (0.01 mol) in dioxane (30 mL) was heated under reflux for 3 hrs.

The reaction mixture was allowed to cool. The separated solid was filtered, washed with ethanol and crystallized from the proper solvent to give (31).

2-chloro-N-(5-(4-chlorophenyl)-6-cyano-4-phenyl-2-thioxo-2,5-dihydro-

1H-pyrano[2,3-d]pyrimidin-7-yl)acetamide (31).

Formed as pale yellow crystals from ethanol; yield (80%); m.p.100—102 °C; ¹H—NMR (DMSO—*d*₆) δ: 4.31 (s, 2H, CH₂), 5.23 (s, 1H, 4H—pyrane), 6.94—8.29 (m, 9H, aromatic H); 10.17 (s, 1H, NH); 11.76 (s, 1H, NH); IR (KBr) v cm⁻¹: 3330, 3212 (2NH), 3065 (CH—arom), 2956 (CH—aliph), 2214 (CN), 1731 (CO) cm⁻¹; MS: *m/z* (%) 469 (M⁺), Anal. calcd for C₂₂H₁₄Cl₂N₄O₂S (469): C, 56.30; H, 3.01; N, 11.94; Cl, 15.11; S, 6.83; Found: C, 56.29; H, 3.00; N, 11.93; Cl, 15.10; S, 6.82 %.

procedure for the preparation of compound (32). Method (A):

A mixture of (11b) (3.92 g; 0.01 mol) and 2-chloroacetyl chloride (30) (0.01 mol) in dioxane (50 mL) was heated under reflux for 24 hrs. The reaction mixture was allowed to cool. The separated solid was filtered, washed with ethanol and crystallized from the proper solvent to give (32).

Method (B):

A mixture of (31) (4.29 g; 0.01 mol) and ammonium acetate was fused for 6 hrs. The reaction mixture was allowed to cool, then triturated with ethanol.

The separated solid was filtered off, washed with water and crystallized from the proper solvent to give (32).

8-(chloromethyl)-5-(4-chlorophenyl)-4-phenyl-2-thioxo-5,7-dihydro-1H-pyrano[2,3-d:6,5-d']dipyrimidin-6(2H)-one (32).

Formed as pale yellow crystals from ethanol; yield (71%); m.p.320—322°C; ¹H—NMR (CDCl₃) δ: 1.59 (s, 1H, NH), 2.18 (s, 1H, NH), 3.50 (s, 2H, CH₂), 3.77 (s, 1H, 4H—pyrane), 7.17—7.61 (m, 9H, aromatic H); MS: IR (KBr) v cm⁻¹: 3143 (NH), 3045 (CH—arom), 2807 (CH—aliph), 1758 (CO) cm⁻¹; MS: *m/z* (%) 469 (M⁺), Anal. calcd for C₂₂H₁₄Cl₂N₄O₂S

(469):C, 56.30; H, 3.01; N, 11.94; Cl, 15.11; S, 6.83; Found: C, 56.29; H, 3.00; N, 11.92; Cl, 15.10; S, 6.82 %.

procedure for the preparation of compound (33).

A mixture of **(11b)** (3.92 g; 0.01 mol) and 2-benzylidenemalononitrile **(6a)** (0.01 mol) in ethanol (50 mL) containing catalytic amount of piperidine was heated under reflux for 8 hrs. The reaction mixture was allowed to cool and poured into crushed ice then acidified with HCl. The separated solid was filtered, washed with water and crystallized from the proper solvent to give **(33)**.

6-amino-5-(4-chlorophenyl)-4,8-diphenyl-2-thioxo-2,5-dihydro-1H-pyrido[3',2':5,6]pyrano [2,3-d]pyrimidine-7-carbonitrile (33).

Formed as pale yellow crystals from ethanol; yield (77%); m.p.110—112 °C; $^1\text{H-NMR}$ (CDCl_3) δ : 4.60 (s, 1H, 4H—pyrane), 6.19 (s, 2H, NH_2), 7.31—7.96 (m, 14H, aromatic H), 9.31 (s, 1H, NH); IR (KBr) ν cm^{-1} : 3331, 3203 (NH_2), 3087 (CH—arom), 2933 (CH—aliph), 2190 (CN) cm^{-1} ; MS: m/z (%) 520 (M^+), Anal. calcd for $\text{C}_{29}\text{H}_{18}\text{ClN}_5\text{OS}$ (520): C, 66.98; H, 3.49; N, 13.47; Cl, 6.82; S, 6.17; Found: C, 66.97; H, 3.47; N, 13.46; Cl, 6.82; S, 6.17 %.

procedure for the preparation of compound (34).

A mixture of **(11b)** (3.92 g; 0.01 mol) and DMF—DMA (0.01 mol) in xylene (30 mL) was heated under reflux for 6 hrs. The reaction mixture was allowed to cool. The separated solid was filtered, washed with ethanol and crystallized from the proper solvent to give **(34)**.

N'-(5-(4-chlorophenyl)-6-cyano-4-phenyl-2-thioxo-2,5-dihydro-1H-pyrano[2,3-d]pyrimidin-7-yl)-N,N-dimethylformimidamide (34).

Formed as brown crystals from ethanol; yield (81%); m.p.210—212 °C;

$^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ : 3.28 (s, 3H, CH_3), 3.43 (s, 3H, CH_3), 4.27 (s, 1H, 4H—pyrane), 7.36—7.61 (m, 11H, aromatic H, $\text{N}=\text{CH}$ and NH); IR (KBr) ν cm^{-1} : 3340 (NH), 2926 (CH—aliph), 2210 (CN) cm^{-1} ; MS: m/z (%) 447 (M^+), Anal. calcd for $\text{C}_{23}\text{H}_{18}\text{ClN}_5\text{OS}$ (447): C, 61.67; H, 4.05; N, 15.63; Cl, 7.91; S, 7.16; Found: C, 61.68; H, 4.06; N, 15.64; Cl, 7.90; S, 7.14 %.

procedure for the preparation of compound (35).

Method (A):

A mixture of **(11b)** (3.92 g; 0.01 mol) and formamide (0.01 mol) in xylene (30 ml) was heated under reflux for 24 hrs. The reaction mixture was allowed to cool and poured into crushed ice then acidified with HCl. The separated solid was filtered, washed with water and crystallized from the proper solvent to give **(35)**.

Method (B):

A mixture of **(34)** (4.47 g; 0.01 mol) and $\text{AcOH}/\text{AcONH}_4$ was heated under reflux for 12 hrs. The reaction mixture was allowed to cool and poured into crushed ice then acidified with HCl. The separated solid was filtered, washed with water and crystallized from the proper solvent to give **(35)**.

6-Amino-5-(4-chlorophenyl)-4-phenyl-1,5-dihydro-2H-pyrimido[5',4':5,6]-pyrano[2,3-d]pyrimidine-2-thione (35).

Formed as brown crystals from ethanol; yield (79%); m.p.150—152 °C; $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ : 4.40 (s, 1H, 4H—pyrane), 7.36 (s, 1H, pyrimidine—H), 8.16—9.70 (m, 9H, aromatic H), 10.63 (s, 1H, NH), 12.10 (s, 2H, NH_2); IR (KBr) ν cm^{-1} : 3460, 3440 (NH_2), 3202 (NH), 2902 (CH—aliph) cm^{-1} ; MS: m/z (%) 421 (M^++1), Anal. calcd for $\text{C}_{21}\text{H}_{14}\text{ClN}_5\text{OS}$ (420): C, 60.07; H, 3.36; N, 16.68; Cl, 8.44; S, 7.64; Found: C,

60.08; H, 3.37; N, 16.70; Cl, 8.43; S, 7.63 %.

ACKNOWLEDGMENT

The authors are very grateful to Prof. Dr. A. E. Khodair, Department of Chemistry, Faculty of Science, Suez Canal University, Ismailia, Egypt, for valuable support and reviewing this manuscript.

REFERENCES

- Abd El-Wahab, A. H. F. (2002). *Acta Pharm.*, 52, 269-280.
- Abdelrazek, F. M.; P. Metz.; O. Kataeva.; A. Jager and S. F. El-mahrouky. (2007). *Archiv der pharmazie*, 340(10), 543-548.
- Afaf, K. El-Ansary.; Azza, T. Taher.; Ahmed, A. El-Rahmany.; Wafaa, E. and Sally. A. El-Awdan. (2013). *Life Science Journal*, 10(2).
- Baucer, V.; Dalalian. H and Safir. S. (1968). *J. Med. Chem*, 11, 1263.
- Bedair, A.H.; Emam, H. A.; El-Hady, N. A.; Ahmed, K. A. R.; Fakery, A. H.; El-Agrody, A. M. (2000). *Farmaco*, 56, 965-973.
- Bedar, A. H.; El-Hady, N. A.; Abd El-Latif, M. S.; Fakery, A. H and El-Arody, A. M. (2000). *Farmaco*, 55, 708-714.
- Bonsignore, L.; G. Loy; D. Secci and A. Calignano. (1993). *European Journal of Medicinal Chemistry*, 28(6), 517-520.
- Bruno, O.; Brullo, C.; Schenone, S.; Bondavalli, F.; Ranise, A.; Tognolini, M.; Ballabeni, V.; Barocelli, E. (2004). *Bioorg. Med. Chem.*, 12, 553-561.
- Bruno, O.; Brullo, C.; Schenone, S.; Ranise, A.; Bonavalli, F.; Barocelli, E.; Tognolini, M.; Magnanini, F.; Ballabeni, V. (2002). *Farmaco*, 57, 753-758.
- Bruno. B. C.; Schenons, S.; Bondavalli, F.; Ranise, A.; Tognolini, M.; Impicciatore, M.; Ballabeni, V.; Barocelli, E. (2006). *Bioorg. Med. Chem.*, 14, 121-130.
- Chabchoub, F.; Messaad, M.; Ben Mansour, H.; Ghdira, L and Salem, M. (2007). *Eur. J. Med. Chem.*, 42, 715-718.
- Cocco, M. T.; Congiu, C.; Onnis. V and Piras. R. (2001). *Farmaco* 56: 741.
- Eid, F. A.; Abd E l-Wahab, A. H. F.; El-Hag ALI, G. A. M and Khafagy, M. M. (2004). *ACTA Pharm.*, 54, 13-26.
- Elagamy, A. A.; El-Taweel, F. M. A. and El-Enein. R. A. N. (2006). *Phosphorus, Sulfur, and silicon*, 181:2155.
- El-Gaby, M. S. A.; Abdel-Gawad, S. M.; Ghorab, M. M and Aly. H. M. (2006). *Phosphorus, Sulfur, and silicon*, 181:279.
- El-saied, A. Aly.; Mohamed, A. Abdo. and Atif. A. El-Gharaby. (2004). *Journal of the Chinese Chemical Society*, 51, 983-990.
- Gamal, A. Elmegeed.; Hanaa, H. Ahmed and Jihan, S. Hussein. (2005). *European Journal of Medicinal Chemistry*, 40, 1283-1294.
- Green, G. R.; Evans. J. M and Vong. A. K. (1995). *Comprehensive Heterocyclic Chemistry II*, A. R. Katritzky, C. W. Rees, and E. F. V. Scriven, Eds, 5, 469.
- Hala., M. Aly and Mona, M. Kamal. (2012). *European Journal of Medical Chemistry*, 47, 18-23.
- Khafagy, M. M.; Abd El-Wahab, A. H. F.; Eid, F. A.; El-agrody, A. M. (2002). *Farmaco*, 57, 715-722.

- Lei, M.; L. Ma and L. Hu. (2011). Tetrahedron Letters, 52(20), 2597-2600.
- Mahmoud, M. M. Ramiz.; Ibrahim, S. Abdel Hafiz. and Mohamed, A. M. Abdel Reheim. (2012). S. Chin. Chem. Soc.5g, 72-80.
- Mansour, S. Al-said.; Mostafa, M. Ghorab.; Mohammed, S. Al-Doosari. and Mostafa. M. Hamed. (2011). J. European Medicinal Chemistry, 46, 201-207.
- Nada, M. Abunada.; Hamdi, M. Hassaneen.; Nadia, G. Kandile and Omar. A. Miqdad. (2008). Molecules, 13, 1501-1517.
- Ozaki et al. (1984). Chem. Abstr, 101, 55035.
- Paghdar. D. J.; Akabari. J. D.; Tala. S. D.; Dhaduk. M. F and Joshi. H. S. (2007). Indian J. Heterocycl. Chem, 17, 113.
- Quintela. J. M.; C. Peinador and M. J. Moreira. (1995). Tetrahedron, 51 (20), 5901.
- Said, A. S. Ghazlan.; Khadija, O. Badahdah. and Ismail, A. Abdelhamid. (2007). Beilstein Journal of Organic Chemistry, 3 (15).
- Saied, A. El-Asslery.; Galal, H. sayed. and Ahmed, F. (2004). Acta Pharm. 54, 143.
- Witte, E. C.; P. Neubert and A. Roesch. (1986). Ger Offen DE3427985, Chemical Abstracts, 104, 224915f.
- Zahed, K. and Baharak, P. (2012). the Scientific World Journal, Article ID 208796, 5.

الملخص العربي

البيريميدين ثيون كأساس في التحضيرات غير المتجانسة الحلقة: تحضير بيرانو (٢، ٣-د) بيريميدين، كرومينو (٢، ٣-د) بيريميدين، بيريدو (٢، ٣، ٥، ٦) بيرانو بيريدين و بيريميديو (٥، ٦، ٤، ٥) بيرانو (٢، ٣-د) بيريميدين

محمد أحمد عليان، إبراهيم سعد عبد الحافظ، محمد أحمد محمود عبد الرحيم

قسم الكيمياء، كلية التربية، جامعة قناة السويس، العريش، مصر

مجموعة جديدة من مشتقات الثيوكسوبييريدين، بيران، بيرانو بيريدين و بيرانو بيريميدين ذات نشاط بيولوجي متوقع تم تحضيرها من خلال تفاعل ٦-فينيل-٢-ثيوكسو-٢،٣-ثنائي هيدروبيريميدين-٤ (٥-هيدرو)-٦-كربونيتريل ٤ و ٧-امينو-٥-٤-كلوروفينيل)-٤-فينيل-٢-ثيوكسو-٢،٥-ثنائي هيدرو-١-هيدرو-بيرانو (٢، ٣-د) بيريميدين-٦-كربونيتريل ١ ب مع بعض الكواشف الالكتروفيلية والنيوكليوفيلية. المركبات الجديدة التي تم تحضيرها تم اثبات تركيبها من خلال تحاليل تحت الحمراء، الرنين النووي المغناطيسي ومطياف الكتلة.

الكلمات الإسترشادية: ثيوكسوبييريدين، بيران، بيرانو بيريدين و بيرانو بيريميدين.

المحكمون:

- ١- أ.د/ على عبد الخالق السباعي أستاذ بقسم حماية البيئة، كلية العلوم الزراعية البيئية بالعريش، جامعة قناة السويس.
- ٢- أ.د/ هالة محمد رفعت أستاذ بقسم الكيمياء، كلية التربية، جامعة قناة السويس.

